This inventor holds 1 USPTO granted patent. Top assignee: Gunma University. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Norio Kubo: Innovator in Cancer Biomarkers
Introduction
Norio Kubo is a distinguished inventor based in Gunma, Japan. He has made significant contributions to the field of medical diagnostics, particularly in the area of pancreatic cancer. His innovative work has led to the identification of a new biomarker that enhances the accuracy of cancer diagnosis.
Latest Patents
Norio Kubo holds 1 patent related to a cancer biomarker in pancreatic cancer and malignant intraductal papillary mucinous neoplasm. His patent focuses on Fucosylated α-acid glycoprotein (fAGP), which has been found to be useful for the diagnosis of pancreatic cancer and malignant intraductal papillary mucinous neoplasm (IPMC). This discovery is particularly important as it aids in the rapid diagnosis of IPMC, improving the accuracy of distinguishing between benign and malignant neoplasms.
Career Highlights
Kubo is affiliated with Gunma University, where he continues to advance research in cancer diagnostics. His work has garnered attention for its potential to significantly impact clinical practices in oncology.
Collaborations
Norio Kubo collaborates with Ken Shirabe, contributing to the advancement of research in their field. Their partnership exemplifies the importance of teamwork in scientific innovation.
Conclusion
Norio Kubo's contributions to cancer biomarker research represent a significant advancement in the field of medical diagnostics. His innovative work has the potential to improve patient outcomes through more accurate and rapid diagnoses.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile